Exhibit 10.8


 


Pursuant
to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit
because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


 


Exclusive
License Agreement 


Between


The
UAB Research Foundation


and


Incysus,
Ltd. 


 


March
10, 2016


 






     


     


    

 


table
of contents


 


	 	Page
	
        Article
        1: Definitions

         
	3
	
        Article
        2: Grant of License

         
	7
	
        Article
        3: Development and Commercialization

         
	9

         

	
        Article
        4: Protection of The Licensed Patents; Patent Prosecution 

         
	10
	
        Article
        5: Financial terms

         
	11
	
        Article
        6: Recordkeeping and Audit Rights

         
	14
	
        Article
        7: Infringement; Enforcement; Other Legal Claims 

         
	15
	
        Article
        8: Other Covenants and Agreements

         
	19
	
        Article
        9: Term and Termination

         
	21
	
        Article 10: Covenants;
        Representations and Warranties; Limitations on UABRF’s Obligations

         
	22
	
        Article
        11: Liability and Indemnification

         
	23
	
        Article
        12: Miscellaneous

         
	25
	 	 
	Exhibit A: Licensed Patents 	29
	 	 
	Exhibit B:  Development and Commercialization Plan	30
	 	 
	Exhibit C: Milestones	31
	 	 
	Exhibit D: Form of Stock Purchase Agreement	33
	 	 
	Exhibit E: Form of Development & Commercialization Progress Report   	34
	 	 
	Exhibit F: Research Plan	35


 






    Page 2 of 35 


     


    

 


EXCLUSIVE LICENSE AGREEMENT


 


This exclusive license
agreement (this “Agreement”) is made and is effective as of March 10th, 2016 (the “Effective Date”)
between The UAB Research Foundation (“UABRF”), a non-profit 501(c)(3) corporation incorporated in the State of Alabama
with its principal place of operations at 701 20th Street South, Birmingham, AL 35233 and Incysus, Ltd. (the “Licensee”),
an entity incorporated in Bermuda, with its principal place of operations at Clarendon
House 2 Church Street Hamilton HM 11, Bermuda.


 


RECITALS


 


WHEREAS, UABRF owns
all right, title and interest in the intellectual property described in UABRF intellectual property disclosure number [*****] entitled
 “[*****]” which was developed by [*****] while employed by the University of Alabama at Birmingham (the “Inventors”),
and has filed for patent protection with respect to such intellectual property; and


 


WHEREAS, UABRF has
the right to grant licenses to the intellectual property and the Licensed Patents (defined below) and desires to have the same
developed and commercialized to benefit the public; and


 


WHEREAS, Licensee,
a biotechnology company created to develop cancer immunotherapy technology, desires an exclusive license to the Licensed Patents;


 


NOW, THEREFORE, in
consideration of the premises described above and the mutual promises and agreements set forth in this Agreement, the Parties agree
as set forth below.


 


Article
1


Definitions


 


The Definitions used in this Agreement
are set forth below.


 


1.1          
“Affiliate” means any Person that directly or indirectly controls, is controlled by, or is under common control
with a Party. “Control” means (i) the beneficial ownership of at least fifty percent (50%) of the voting securities
of a Person with voting equity, or (ii) the power to direct or cause the direction of the management or policies of a Person.


 


1.2          
“Agreement” means this agreement, as amended from time to time in accordance with the terms and conditions set
forth in this agreement.


 


1.3          
“Applicable Law” means all laws, statutes and regulations promulgated by all Regulatory Authorities and all
Governmental Authorities.


 


1.4           “Change
in Control” means, with respect to an entity, a transaction or series of related transactions as a result of which a
Person or group of Persons acting in concert directly or indirectly acquires control of the entity or acquires any of the
entity’s assets that are, individually or in the aggregate, material to its performance under this Agreement. The
transactions may be in any form or combination of forms, including an issuance of voting securities, a grant of one or more
proxies, the establishment of a voting agreement, a merger (whether or not the entity survives), a share exchange, or a
reorganization, a recapitalization or an asset sale.


 






    Page 3 of 35 


     


    

 


1.5          
“Development and Commercialization Plan” means development, manufacturing, marketing, and commercialization
activities proposed to be undertaken by the Licensee with respect to the Licensed Patents as set forth on attached Exhibit B.


 


1.6          
“Disclaimed Licensed Patent(s)” means any Licensed Patent in respect of which the Licensee decides not to pursue
protective rights, undertake, or be responsible for, the payment of Protection Expenses, as described in Section 4.1(e) and (f)
of this Agreement.


 


1.7          
“First Commercial Sale” means the first Sale of a Licensed Product to a Third Party.


 


1.8          
“For Value” means any consideration, remuneration or benefit of any kind, whether received directly or indirectly,
including, but not limited to, cash, equity, debt, preferential treatment, including waiver, rebate, discount, etc.


 


1.9          
“Governmental Authorities” means, with respect to each country or jurisdiction, all legislative and governmental
authorities, bodies, commissions, agencies or other instrumentalities of such country or jurisdiction.


 


 1.10         “Infringement Notice” is defined in Section 7.1 of this Agreement.




 


 1.11         “Inventors” is defined in the first recital of this Agreement.




 


1.12        
“Licensed Field of Use” means cellular therapies in humans.


 


1.13       
“Licensed Patents” means (a) the patents and/or patent applications set forth on attached Exhibit A, (b) any
U.S. and foreign patents and patent applications that directly or indirectly claim priority to such patents and patent applications,
(c) all patents proceeding from any of the foregoing, and (d) all foreign equivalents, divisionals, continuations, continuations-in-part,
reissues, reexaminations, substitutions and extensions of any patent or patent application described in (a) – (c) above.
Licensed Patents does not include any patent and/or patent application that is a Disclaimed Licensed Patent.


 


1.14        
“Licensed Product” means any product or part thereof, composition, material, process, or service, the development,
manufacture, use, import, export, offer for sale, or sale of which is covered by, or which cannot be undertaken or completed without
infringing, a Valid Patent Claim set forth in any Licensed Patent. For the avoidance of doubt, for purposes of Section 5.5, any
product or part thereof, composition, material, process, or service which would be deemed to be a Licensed Product if such product
or part thereof, composition, material, process, or service were sold in any country or jurisdiction in which a Valid Patent Claim
exists shall still be considered to be a Licensed Product with respect to sales in a country or jurisdiction in which no Valid
Patent Claim exists.


 






    Page 4 of 35 


     


    

 


 1.15         “Licensed Territory” means worldwide.




 


1.16        
“Net Sales” means the gross amount set forth on the invoice relating to any Sale of a Licensed Product, less
(a) discounts actually allowed, (b) rebates, price reductions, rebates to social and welfare systems, charge backs, government
mandated and similar rebates, (c) credits for claims, allowances, retroactive price reductions or returned goods, (d) prepaid freight
and insurance, (e) customs duties, sales taxes or other governmental charges actually paid in connection with such Sale (but excluding
income tax), transportation, or delivery (including annual fees due under Section 9008 of the United States Patient Protection
and Affordable Care Act of 2010 (Pub. L. No. 111-48); (f) outbound transportation expenses prepaid or allowed; and (g) invoiced
amounts written off as uncollectible [*****]. Where a Licensed Product is not used, transferred or exchanged For Value, the Net
Sales will be the net invoice price of products of similar kind and quality, sold or transferred For Value at similar quantities,
currently being offered by the Licensee, a Sublicensee or by other manufacturers. Where there is no comparable sale or transfer
For Value, the Net Sale will be the Licensee’s or Sublicensee’s cost of manufacture, determined by the Licensee’s
or Sublicensee’s customary accounting procedures, plus [*****]. Components of Net Sales shall be determined in the ordinary
course of business using the accrual method of accounting in accordance with generally accepted accounting practices.


 


1.17        
 “Non-Commercial Research Purposes” means any use and practice for academic research and educational purposes,
including collaboration with other non-profit entities, but expressly excluding any commercial or for-profit purposes or uses.


 


1.18        
“Non-Royalty Income” means anything received by Licensee or its Affiliates or Sublicensees For Value in consideration
of (i) the transfer of Licensed Product in a transaction or portion of a transaction that is not structured to generate royalty
payments based on Net Sales; or (ii) the grant of a right (through sublicense or otherwise) to practice the Licensed Patents and/or
to make, have made, use or sell Licensed Product in a transaction or portion of a transaction that is not structured to generate
royalty payments based on Net Sales.  For purposes of clarity, Non-Royalty Income includes upfront fees, milestone payments
and advances and any consideration received by Licensee from the purchase by a Sublicensee of shares of the Licensee in exchange
for a transaction or right as described in (i) or (ii) above. Non-Royalty Income shall not include [*****].


 


 1.19         “Parties” means UABRF and the Licensee and each of them individually is a “Party”.




 


1.20        
“Person” means an individual, corporation, partnership, trust, business trust, association or any other entity
with a separate legal identity, including the Parties.


 


 1.21         “Proprietary Information” is defined in Section 8.4 of this Agreement.




 


1.22        
“Protection Activities” means preparation of, obtaining, filing for, securing, pursuing, prosecuting, and continuing
or maintaining the patents and patent applications, including through participation in post-grant review, inter partes review,
ex parte reexamination, or opposition proceedings.


 






    Page 5 of 35 


     


    

 


1.23       
 “Protection Expenses” means all actual, out-of-pocket legal fees, costs and expenses reasonably incurred by
UABRF in the performance of the Protection Activities, such fees, costs and expenses to be documented by written invoice.


 


1.24        
“Regulatory Documents” means any document or information prepared for submission to, or submitted to any Governmental
Authority with respect to the Licensed Patents that have been provided to UABRF by UAB and/ or an Inventor. Regulatory Documents
shall include, but not be limited to, documents related to investigational new drug applications.


 


1.25        
 “Regulatory Authority” means, with respect to any particular country or jurisdiction, the Governmental Authority
with the primary responsibility for the evaluation or approval of cellular therapy products and processes before such products
and/or services can be tested, marketed, promoted, distributed or sold in such country or jurisdiction, including Governmental
Authorities that have jurisdiction over the pricing of such products. The term Regulatory Authority includes the Food and Drug
Administration of the United States.


 


1.26        
“Representative(s)” means, with respect to each Party and their Affiliates, all directors, officers, employees,
agents and advisors and with respect to UABRF only, the trustees of its Affiliate, UAB and any Third Party described in Section
8.4(d) to whom the Receiving Party provides the Proprietary Information in accordance with the conditions set forth in Section
8.4(d).


 


1.27        
“Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period from
the first sale of such Licensed Product in such country until the earlier of: (a) expiration of the last Valid Patent Claim of
a Licensed Patents covering such Licensed Product in such country; or (b) fifteen (15) years from First Commercial Sale of such
Licensed Product in such country.


 


1.28        
 “Sale or Sales” means any use, transfer or exchange, For Value, of a Licensed Product. Sales include all Sales
by the Licensee and its Affiliates and Sublicensees, and include any transfer by the Licensee to an Affiliate or Sublicensee where
there is no subsequent Sale (i.e. the Licensed Product is not further resold or transferred). For the avoidance of doubt, Sales
shall not be deemed to include (a) any transfer by the Licensee where there is a subsequent Sale of the Licensed Product; only
the subsequent Sale is used to calculate any amount due, (b) the use, performance or provision of a Licensed Product for research
and development purposes, including preclinical, clinical or translational trials or for compassionate use or as samples or (c)
reasonable distributions as samples or given as donations for indigent use. A Licensed Product shall be considered sold when the
Licensed Product is shipped or invoiced, whichever is earlier.


 


1.29        
 “Sublicensee” means a Person to whom the Licensee has granted a sublicense pursuant to Section 2.5 of this
Agreement.


 


1.30        
“Technical Information” shall mean technical information, know-how, processes, procedures, compositions, devices,
methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by one or more of the Inventors
and disclosed to UABRF by the Inventors before the Effective Date which are not covered by a Valid Patent Claim but which is/are
necessary for practicing one or more invention claimed in the Licensed Patents.


 






    Page 6 of 35 


     


    

 


1.31          “Term” is defined in Section
9.1 of this Agreement.


 


1.32         “Third Party” means any
Person other than the Parties and their Affiliates and Representatives.


 


1.33         “United States” means
the United States of America.


 


1.34         “United States Government”
means the Federal Government of the United States.


 


1.35         “Valid Patent Claim” means
(i) a pending patent claim included within the Licensed Patents or (ii) an issued and unexpired patent claim included within the
Licensed Patents which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental
Authority of competent jurisdiction, to which an appeal has not or cannot be taken within the time allowed for appeal, and which
has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.


 


Article
2


Grant
of License


 


2.1          
Grant of License. Subject to the terms and upon the conditions set forth in this Agreement, UABRF hereby grants to the Licensee
and its Affiliates an exclusive right and license to (a) practice the Licensed Patents and (b) make, have made, develop, have developed,
manufacture, have manufactured, use, have used, rent, lease, offer to sell, sell, have sold, distribute, import and export Licensed
Products, within the Licensed Field of Use in the Licensed Territory during the Term. UABRF shall transfer or provide to Licensee
a copy of all Technical Information requested by the Licensee, which has not been previously provided, within [*****] of the Effective
Date. UABRF shall transfer or provide a copy to Licensee of all Regulatory Documents (i) within [*****] of UABRF’s receipt
of such from the Inventors or (ii) within [*****] of the submission or receipt of such Regulatory Documents by UABRF, whichever
shall occur first. For the avoidance of doubt, UABRF shall promptly after the Effective Date transfer to Licensee a copy any investigational
new drug application related to any Licensed Patent.


 


2.2           Rights
of the United States Government. It is understood that a United States Governmental Authority (through an award numbered [*****])
has funded research, during the course of or under which the Licensed Patents were conceived or made. The United States Government
is entitled, as a right, under the provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Chapter 37 of the
Code of Federal Regulations (“Bayh-Dole”), to a non-exclusive, non-transferable, paid-up license to practice or have
practiced and use the affected Licensed Patents for governmental purposes. The Licensee acknowledges that the rights and license
granted to it pursuant to this Agreement are subject to any and all rights of the United States Government.


 


2.3           Reservation
of Rights by UABRF and its Affiliates. UABRF reserves the right, for itself and for its Affiliates, to:


 






    Page 7 of 35 


     


    

 


		(a)	practice and use, and to permit its Representatives to practice and use, the Licensed Patents within
the Licensed Field of Use solely for Non-Commercial Research Purposes;



		(b)	grant to non-profit academic, educational or research institutions and Governmental Authorities,
non-exclusive, royalty-free licenses to practice and use the Licensed Patents within the Licensed Field of Use solely for Non-Commercial
Research Purposes;



		(c)	permit their respective Representatives to disseminate and publish scientific findings from research
related to the Licensed Patents; and



		(d)	practice, use and otherwise commercialize, including licensing, the Licensed Patents to Third Parties
for applications and uses outside of the Licensed Field of Use.



 


2.4           Title
Remains with UABRF. All right, title and interest in and to the Licensed Patents remains with UABRF. Except as provided in
this Agreement, no express or implied licenses with respect to the Licensed Patents or any other rights are transferred or granted
to the Licensee by implication, estoppel or otherwise. UABRF represents and certifies that it has the legal right to grant the
rights under this Agreement.


 


2.5           Right
to Grant Sublicenses. The Licensee has the right to grant sublicenses to any Person under this Agreement on the following terms
and conditions:


 


		(a)	the execution of a sublicense shall not in any way diminish, reduce or eliminate any of the Licensee’s
obligations under this Agreement;



		(b)	any sublicense so granted is limited to the Licensed Field of Use;



		(c)	any sublicense so granted shall be subject and subordinate to, and consistent with, the terms of
this Agreement;



		(d)	the Licensee may not [*****];



		(e)	any sublicense shall also provide that, in the event this Agreement is terminated or upon the expiration
of the Term, (i) the Licensee shall notify the Sublicensee of the termination or expiration, (ii) the sublicense will terminate
simultaneously with the termination or expiration of this Agreement, and (iii) the Sublicensee may enter into a license agreement
with UABRF on substantially the same terms as the Sublicensee’s sublicense with the Licensee with UABRF’s approval,
provided that [*****] or [*****];



		(f)	all sublicenses are to be For Value;



		(g)	the Licensee shall provide UABRF with a copy of any such sublicense granted by it under this Agreement
promptly after the execution of the sublicense;



		(h)	all such copies of sublicense agreements may be redacted to exclude confidential scientific information
and other information required by the Sublicensee to be kept confidential, provided that [*****] shall be retained and shall not
be redacted; the disclosure of sublicense agreements to UABRF shall be subject to the confidentiality obligations set forth in
this Agreement;



		(i)	UABRF is a third party beneficiary to each sublicense and each agreement evidencing a sublicensing
arrangement shall include a statement and an acknowledgement by the Sublicensee to this effect; and



 






    Page 8 of 35 


     


    

 


		(j)	Subject to the sublicensing terms in this Section 2.5, Sublicensees may be permitted, on a case-by-case
basis, to further sublicense their rights to practice the Licensed Patents.  Prior to the execution of any sublicense agreement
which allows a Sublicensee to further sublicense, Licensee shall present to UABRF a reasonably detailed business justification
for the proposed sublicense, as well as [*****], for UABRF’s review and approval.  Licensee shall proceed with execution
of the proposed sublicense agreement only with UABRF’s prior written consent, such consent shall not be unreasonably withheld.



 


Article
3


Development
and Commercialization


 


3.1           Development
and Commercialization Plan. During the Term, the Licensee shall use good faith, reasonable commercial efforts to develop,
manufacture, commercialize and market the Licensed Patents through a diligent program designed to accomplish the commercial exploitation
of the same and to make the technology covered by or embedded in the Licensed Patents available to the general public in accordance
with the procedures and practices that are usual and customary for similar technologies and industries utilizing those resources
that would be employed by the Licensee of a product or compound of similar market potential at a similar stage in its development
or product life as the Licensed Patents taking into account, without limitation, issues of safety and efficacy, product profile,
intellectual property situation, regulatory environment and other relevant scientific and commercial factors). The Parties acknowledge
that the Licensee has provided to UABRF the Development and Commercialization Plan set forth on attached Exhibit B which sets forth
its current development and commercialization objectives. The Parties further acknowledge and agree that the Development and Commercialization
Plan is, and the development and commercialization milestones, each set forth on attached Exhibits B and C, are reasonable.


 


3.2           Amendment
of Development and Commercialization Plan and Milestones. All variations and deviations from and changes to the Development
and Commercialization Plan and milestones [*****].


 


3.3           Development
and Commercialization Report. The Licensee shall provide UABRF not more than once annually written progress reports detailing
generally the activities of the Licensee, its Affiliates and all Sublicensees relating to the Development and Commercialization
Plan (Exhibit B) and if any of the Milestones on Exhibit C have been attained. Such reports are to be provided substantially in
the format shown in Exhibit E.


 


3.4           Regulatory
Approvals. With respect to each Licensed Product, and to the extent regulatory approval is required, the Licensee shall use
its reasonable efforts to obtain the approval of each applicable Regulatory Authority prior to the First Commercial Sale in each
country/jurisdiction in which the Licensee intends to sell Licensed Products.


 


3.5           Patent
Markings. If required by Applicable Law, all Licensed Products manufactured and/or sold shall be marked in such a manner as
to conform to the Applicable Law of such country/jurisdiction.


 






    Page 9 of 35 


     


    

 


3.6           Manufacturing
in the United States. The Licensee shall use its best efforts to substantially manufacture in the United States any Licensed
Products sold in the United States that incorporates any invention or intellectual property owned by UABRF and licensed to the
Licensee under this Agreement that was developed using funds provided by a United States Governmental Authority.


 


Article
4


Protection
of The Licensed Patents; Patent Prosecution 


 


4.1           Future
Protection Activities.


 


		(a)	UABRF Retains Primary Responsibility. Subject to the terms and conditions set forth
in this Agreement, UABRF shall, from the Effective Date, continue to be primarily responsible for undertaking all Protection Activities
relating to the Licensed Patents. UABRF shall select such legal counsel as it deems appropriate to assist it in this process, provided
that such counsel is reasonably acceptable to Licensee.



		(b)	Co-operation of the Licensee. The Licensee shall reasonably cooperate with
UABRF and its designated legal counsel in connection with the Protection Activities.



		(c)	Consultation with the Licensee. UABRF shall, and shall cause its designated legal
counsel to, consult with the Licensee in connection with such Protection Activities, and the Licensee shall be given reasonable
opportunity to discuss, advise and review issues with UABRF and its designated legal counsel in connection therewith.



		(d)	Foreign Protection Requested by the Licensee. The Licensee must notify UABRF in writing
identifying in which foreign countries and jurisdictions, if any, the Licensee wishes to undertake Protection Activities with respect
to any Licensed Patents. Exhibit A shall be amended accordingly to reflect these designations.



		(e)	Foreign Patent Protection Not Requested by the Licensee. UABRF may elect to undertake
Protection Activities with respect to any Licensed Patents in any country or jurisdiction not so designated by the Licensee pursuant
to Section 4.1(d) above. In such cases (i) UABRF shall be responsible for all Protection Expenses incurred in connection therewith,
and the Licensee shall not be responsible for such expenses, (ii) the Licensed Patents so affected shall no longer be deemed to
be licensed to the Licensee and shall be deemed to have been disclaimed by the Licensee (each, a “Disclaimed Licensed Patent”),
(iii) the Licensee shall forfeit and shall no longer have any rights or obligations with respect thereto and (iv) Exhibit A shall
be amended accordingly to delete the affected Licensed Patents.



		(f)	Disclaimed Licensed Patent. The Licensee may, at any time during the Term,
                                                               provide at least [*****] written notice to UABRF that it no longer wishes to be responsible for the Protection Expenses in
                                                               connection with one or more Licensed Patents. In such cases, (i) the Licensee shall continue to be responsible for all
                                                               Protection Expenses incurred in connection therewith until the expiration of such [*****] notice period and thereafter shall
                                                               not be responsible for such expenses, (ii) the Licensed Patents so affected shall no longer be deemed to be licensed to the
                                                               Licensee and shall be deemed to have been disclaimed by the Licensee (each, a “Disclaimed Licensed Patent”),
                                                               (iii) the Licensee shall forfeit and shall no longer have any rights or obligations
with respect thereto and (iv) Exhibit A shall be amended accordingly to delete the affected Licensed Patent.






 






    Page 10 of 35 


     


    

 


4.2           Information
to the Licensee. UABRF shall provide the Licensee with copies of all issued patents relating to the Licensed Patent. UABRF
shall provide copies of all patent applications and all filings, correspondence and other related documentation pertaining to prosecutorial
matters arising from the Protection Activities, including, but not limited to, all office actions, requests for examinations and
restriction requirements.


 


Article
5


Financial
Terms 


 


5.1         
License Issue Fee. Within [*****] of the Effective Date, the Licensee shall pay to UABRF a non-refundable, non-creditable
license issue fee of [*****].


 


5.2         
Future Protection Expenses. Beginning [*****] after the Effective Date, or [*****] before the filing of the non-provisional
application of a Licensed Patent, whichever is earlier and during the Term and with respect to the Licensed Patents, other than
Disclaimed Licensed Patents, the Licensee will be financially responsible for the payment of all Protection Expenses incurred after
the Effective Date. The Licensee shall pay such amounts to UABRF within [*****] of receipt of an invoice for the same from UABRF.
UABRF shall be responsible for all Protection Expenses incurred in connection with each Disclaimed Licensed Patent in countries/jurisdictions
not designated by the Licensee pursuant to Section 4.1(d) above or after the expiration of the notice period referred to in Section
4.1(f) above.


 


5.3         
Issuance of Stock in the Licensee to UABRF. On or promptly following the Effective Date, the Licensee shall issue
to UABRF shares in the Licensee initially equivalent to a two and one-half percent (2.5%) ownership interest in Licensee, prior
to raising any outside capital to fund the Licensee, which ownership interests shall be subject to the terms and conditions of
the Stock Purchase Agreement, dated of even date herewith, a copy of which is attached to this Agreement as Exhibit D. The equity
position held by UABRF shall not be diluted until the Licensee has raised at least Twenty Million Dollars ($20,000,000.00) through
one or more rounds of investment in equity securities of the Company (or debt securities of the Company that are convertible into
or exchangeable for equity securities of the Company) (the “Threshold Amount”). Thereafter, the shares held by UABRF
may be diluted only upon the same terms and conditions [*****], until completion of an initial public offering of the Licensee’s
common stock.


 


5.4          
Funding of Research Program. The Licensee hereby agrees to support a research program, as set forth in the Research
Plan attached hereto as Exhibit F, to be carried out by UABRF’s Affiliate, the University of Alabama at Birmingham. The Parties
anticipate that the Licensee’s support of such research program shall take the form of a series of sponsored research agreements
and/or clinical trial agreements, as applicable, which the University of Alabama at Birmingham and Licensee agree to negotiate
in good faith.


 






    Page 11 of 35 


     


    

 


5.5        
 Running Royalty Payments. During the Term and with respect to each country or jurisdiction within the Licensed Territory
in which a Valid Patent Claim exists, the Licensee shall pay to UABRF royalties on all Net Sales of Licensed Products as set forth
below:


 


	Entity Accomplishing Sales	Royalty Rate to UABRF
	Licensee or Licensee’s Affiliates	[*****]
	Sublicensees 	[*****]


 


These
payments shall be made on all Net Sales arising in such country/jurisdiction until the expiration of the last Valid Patent Claim
in that country/jurisdiction. With respect to each country or jurisdiction within the Licensed Territory in which no Valid
Patent Claim exists, Licensee agrees to pay to UABRF a running royalty of [*****] on all Net Sales arising in each such country/jurisdiction
during the Term of this Agreement. For the avoidance of doubt, a running royalty shall only be payable to UABRF one time upon the
Sale of any Licensed Product to an end user or consumer. All amounts owing
to UABRF under this section shall be paid on a quarterly basis, on or before the [*****] following the end of the calendar quarter
in which such amounts were earned. 


 


5.6          
Anti-Stacking Provision. If, at any time, Licensee discovers that any Licensed Product or the use thereof in the
Licensed Field of Use or the practice of any Licensed Patent infringes claims of an unexpired patent or patents other than those
in the Licensed Patents, Licensee may, if it has not already done so, negotiate with the owner of such patents for a license on
such terms as Licensee deems appropriate. Should the license with the owner of such patents require the payment of royalties or
other consideration to such owner then the royalties otherwise payable under this Agreement may be reduced by the amount payable
[*****] to the other patent owner(s), but in no event shall the royalties payable under this Agreement be reduced by more than
[*****]. To clarify, Licensee and UABRF agree that under no circumstance shall UABRF’s royalty amount under Section 5.5 be
less than (a) [*****] when the Licensee or one of its Affiliates is the entity generating Net Sales and (b) [*****] when a Sublicensee
is the entity generating Net Sales. If a combination product incorporates a product based on a patent (other than a Licensed Patent)
to which Licensee has secured rights via an agreement with the patent owner and the owner of such patent requires the payment of
royalties or other consideration to such owner, then the royalties otherwise payable under this Agreement may be reduced by the
amount payable [*****] to the other patent owner(s), but in no event shall the royalties payable under this Agreement be reduced
by more than [*****].


 


5.7          
Lump Sum Royalties on Cumulative Net Sales. The Licensee shall pay to UABRF a lump sum amount when the cumulative
Net Sales accomplished by Licensee, its Affiliates and Sublicensees reaches the amounts set forth below in any calendar year. The
table below sets out the cumulative Net Sales amounts and corresponding lump sum payments owed to UABRF:


 


	Cumulative Net Sales Amount Reached in Calendar Year	Lump Sum Due to UABRF
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]


 






    Page 12 of 35 


     


    

 


All amounts owing to
UABRF under this section shall be paid within [*****] of the close of any calendar year in which one of the above amounts is reached
in cumulative Net Sales made by Licensee, its Affiliates and Sublicensees.


 


5.8         
Milestone Payments. During the Term, the Licensee shall pay to UABRF the development and commercialization milestone
payments set forth in Exhibit C. Each such milestone payment is in consideration of this Agreement and shall be due to UABRF without
deduction or adjustment relating to milestones payable to other Third Parties, shall be non-creditable and non-refundable and shall
be due within [*****] of achievement. The Licensee shall provide written notice to UABRF to accompany the payment identifying the
milestone that has been achieved.


 


5.9          
Non-Royalty Income. The Licensee shall pay to UABRF the amounts as laid out in the chart below on any and all Non-Royalty
Income received by it during the Term with such payments being made to UABRF on or before the [*****] of receipt by the Licensee.
All such payments shall be accompanied by a written notification of the nature and origin of the Non-Royalty Income upon which
the payment is based, the identity of the source of such Non-Royalty Income and, if such Non-Royalty Income was received by the
Licensee or generated in a foreign currency, the rate of currency conversion and the date such conversion was calculated as described
in Section 5.13 of this Agreement. In the event that the Licensee receives Non-Royalty Income that is not cash or a cash equivalent,
the percentage of non-cash payments shall be calculated as a percentage of the then current fair market value of such non-cash
consideration. For purposes of clarity and by example only, consideration received by the Licensee in a transaction in which [*****]
or in which [*****] would not be considered Non-Royalty Income. Further, [*****] shall mean [*****] and Licensee resolves all queries
or requests for clarification made by Licensee to sites participating in the trial. The term [*****] as used below shall be as
defined in Exhibit C.


 


	YEAR 	
        PARTICIPATION PCT. IN

        NON-ROYALTY INCOME

	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]


 


5.10       
Royalty Reports. During the term of this Agreement, Licensee shall provide UABRF written reports semiannually until
the first Sale of a Licensed Product and quarterly thereafter showing:


		i.	the occurrence of any event triggering a Milestone Payment obligation or any other payment in accordance with Section 5.8 above;
and



		ii.	a summary of all reports provided to LICENSEE by LICENSEE'S Sublicensees, including the names and addresses of all Sublicensees;
and



		iii.	the amount of any consideration received by LICENSEE from Sublicensees and an explanation of the contractual obligation satisfied
by such consideration;



		iv.	within a given fiscal quarter, the gross selling price and the number of units of all Licensed Products (identified by product
number/name) Sold in each country of the Licensed Territory, together with the calculations of Net Sales; and



		v.	within a given fiscal quarter, the royalties payable in U.S. Dollars which accrued hereunder; and



		vi.	within a given fiscal quarter, the exchange rates, if any, used in determining the amount due.



 






    Page 13 of 35 


     


    

 


5.11       
Address for Payments. Except as otherwise directed by UABRF, all amounts due to be paid by the Licensee to UABRF
pursuant to this Agreement shall be paid to UABRF at the address set forth below its signature on the signature page of this Agreement.


 


5.12       
Late Payment Penalty. The balance of any amount which remains unpaid more than [*****] after it is due to UABRF may
be assessed interest until paid at the rate equal to the lesser of [*****] or the maximum amount allowed under Applicable Law.
However, in no event shall this interest provision be construed as a grant of permission for payment delays.


 


5.13        
Currency Conversion. All amounts due to be paid to UABRF pursuant to this Agreement shall be made in United States
dollars. Any and all amounts received by the Licensee or generated in foreign currency shall be converted into United States dollars
at the official rate of exchange from such currency to United States dollars at the rate quoted in the Wall Street Journal (United
States edition) for the daily average over the calendar quarter in which running royalties are due and payable to UABRF or on a
business day no earlier than five (5) business days before payment is made to UABRF.


 


5.14       
Taxes. UABRF is exempt from paying income taxes under United States law; therefore, all payments made by Licensee
under this Agreement shall be made without deduction for taxes, assessments or other charges of any kind that are typically imposed
by United States Governmental Authority. Any tax required to be withheld by the Licensee under the laws of any foreign
country or jurisdiction for the account of UABRF shall be promptly paid by the Licensee for and on behalf of UABRF to the appropriate
Governmental Authority, and the Licensee shall use reasonable commercial efforts to furnish UABRF with proof of payment of such
tax, together with official or other appropriate evidence issued by the applicable Governmental Authority. Any such amounts actually
paid on UABRF’s behalf shall be deducted from any amounts due to be paid to UABRF under this Agreement.


 


5.15        
No Refund/Offset. Except as otherwise expressly provided under this Agreement, no amounts payable to UABRF under
this Agreement are refundable or may be offset, including any amounts paid prior to or during the period of a Patent Challenge
under Section 7.7, even if the Patent Challenge is successful or it is otherwise determined that the Licensed Patents are invalid
or unenforceable.


 


Article
6


Recordkeeping



 


6.1          
Books and Records. The Licensee shall keep complete and accurate books, accounts and other records and documentation
necessary to ascertain all transactions and events pursuant to which payments due to UABRF pursuant to this Agreement arise and
are accrued and to verify the accuracy and completeness of such amounts. All such books, accounts and other records and documentation
shall be kept at the Licensee’s principal place of business for a period of not less than [*****] following the end of the
calendar year to which they pertain.


 






    Page 14 of 35 


     


    

 


6.2          
Right to Audit. For the Term, UABRF shall have the right to have the Licensee’s books and records audited by
a qualified, independent accounting firm of its choosing, under appropriate confidentiality provisions such as those set forth
in Section 8.4 of this Agreement, to ascertain the accuracy of the reports and payments due to UABRF under this Agreement and compliance
by the Licensee, its Affiliates and its Sublicensees with their obligations pursuant to this Agreement and any sublicense. Such
audit shall be conducted upon reasonable advance notice, during normal business hours and in a manner that does not interfere unreasonably
with the Licensee’s business but not more than once in any [*****] period. If any such examination reveals that the Licensee
has underpaid or underreported any amount due under this Agreement to UABRF for any calendar quarter examined, the Licensee shall
promptly pay to UABRF the amount so underpaid or underreported.


 


6.3         
Reimbursement of Cost of Audit. If any such examination reveals that the Licensee has underpaid or underreported
any amount due under this Agreement to UABRF by more than [*****] for any calendar quarter examined, the Licensee shall immediately
reimburse UABRF the full costs and expenses incurred by it with respect to the audit.


 


Article
7


Infringement;
Enforcement; Other Legal Claims


 


7.1          
Notification of Infringement and Other Potential Claims. During the Term, each Party shall provide prompt written
notice to the other Party of any actual infringement or suspected/potential infringement of the Licensed Patents in the Licensed
Territory of which such Party is or becomes aware and shall provide, to the extent reasonable and practicable, any available evidence
of such infringement by a Third Party (an “Infringement Notice”). In addition, during the Term, the Licensee shall
also provide prompt written notice to UABRF of any facts, circumstances or events which negatively impact or which the Licensee
reasonably believes negatively impact the ability of the Licensee or its Affiliates or Sublicensees to exercise their rights or
to perform their obligations under this Agreement or any sublicense granted under this Agreement or which negatively impact UABRF’s
intellectual property rights in the Licensed Patents, and the Licensee shall provide, to the extent reasonable and practicable,
details of (i) the potential claim(s) or cause(s) of action which the Licensee reasonably believes it has or which may be asserted
by the Licensee against a Third Party and any actual claims or causes of action asserted by any Third Party against the Licensee
or the potential claim(s) or cause(s) of action the Licensee reasonably believes a Third Party may assert against the Licensee,
and (ii) sufficient information to enable UABRF to evaluate the issues and the potential effect and impact such claims may have
on its rights under this Agreement and the Licensed Patents (a “Potential Claim Notice”).


 


7.2           Licensee
Right to Pursue/Prosecute. During the Term, the Licensee shall have the right to (i) resolve, in the Licensed Field of
Use and in the Licensed Territory, any suspected/potential infringement and prosecute any infringement of any Licensed
Patents, and/or (ii) resolve any actual or potential claim or cause of action the Licensee believes it has or may have or
which a Third Party has or may have against the Licensee which negatively impact or which the Licensee reasonably believes
negatively impact the ability of the Licensee or its Affiliates or Sublicensees to exercise their rights or to perform their
obligations under this Agreement or any sublicense granted under this Agreement, in its own name and at its own expense,
provided:


 






    Page 15 of 35 


     


    

 


		(a)	the affected Licensed Patents remain exclusively licensed to the Licensee and are not a Disclaimed
Licensed Patent;



		(b)	the claim relates to a Valid Patent Claim; and



		(c)	the Licensee remains in compliance in all material respects with its obligations under this Agreement.



 


The Licensee shall use its best efforts
to abate or terminate such infringement or resolve any other actual or potential claim(s) or cause(s) of action without resorting
to litigation, which may include negotiating and executing a sublicense agreement that complies with the terms of Section 2.5 of
this Agreement. Before the Licensee commences an action with respect to any infringement or potential infringement or commences
an action filed by, or responds to an allegation raised by, a Third Party, it shall give careful consideration to the views of
UABRF and the potential effects on the public interest in making its decision whether or not to sue or how to respond. UABRF shall
use reasonable efforts to cooperate with the Licensee in connection with any remedial action undertaken by the Licensee and shall
be responsible for the costs and expenses incurred by it and for those costs and expenses incurred by it at the reasonable request
of the Licensee with respect to such cooperation.


 


		7.3	Control of Suit; Joinder; Expenses.



 


		(a)	Initiated by the Licensee. If the Licensee wishes to commence a lawsuit, it must do so within
[*****] following the date of the relevant Infringement Notice and/or Potential Claim Notice, and it shall bear all costs and expenses
incurred by it in connection with such lawsuit. UABRF shall cooperate fully with the Licensee in connection with such lawsuit and
shall be responsible for the costs and expenses incurred by it and for those costs and expenses incurred by it at the reasonable
request of the Licensee with respect to such cooperation.



 


		(b)	Initiated by UABRF. If the Licensee elects not to exercise its right to commence, or fails
to commence, an action within [*****] of the date of the relevant Infringement Notice and/or Potential Claim Notice, UABRF may
do so at its own expense, and shall retain sole control over the direction of such lawsuit. The Licensee shall cooperate fully
with UABRF in connection with such lawsuit and shall be responsible for the costs and expenses incurred by it with respect to such
cooperation. If UABRF files an infringement or other lawsuit, the Licensee may not thereafter commence a lawsuit against the same
infringing or other party with respect to the same acts of infringement or facts or circumstances which are the subject of UABRF’s
lawsuit or with respect to which settlement is reached by the infringing or other party and UABRF.



 


		(c)	Joinder by UABRF. UABRF, to the extent permitted by Applicable Law, may elect to join in
as a party to any lawsuit relating to the Licensed Patents, UABRF’s intellectual property rights in the Licensed Patents
and/or the Licensee’s ability to exercise its rights or perform
its obligations under this Agreement initiated by the Licensee, in which case, both Parties shall jointly control the lawsuit and
shall equally share the responsibility of all legal fees, costs and expenses, unless otherwise agreed to by the Parties. The Licensee
may not join UABRF in as a party to any lawsuit initiated by it without the prior written consent of UABRF, which such consent
shall not be unreasonably withheld, and without prior written agreement between the Parties as to the responsibility between the
Parties for all costs and expenses incurred by the Parties. If UABRF is involuntarily joined as a party to a lawsuit initiated
by the Licensee, the Licensee shall pay all legal fees, costs and expenses incurred by UABRF arising out of such joinder and participation,
including, but not limited to legal fees, costs and expenses reasonably incurred by legal counsel selected and retained by UABRF
to represent it in such lawsuit. While UABRF remains a party to any lawsuit initiated by the Licensee, UABRF may not thereafter
commence a lawsuit against the same Third Party with respect to the same acts or omissions which are the subject of the Licensee’s
lawsuit or with respect to which settlement is reached by the Third Party, the Licensee and UABRF.






 






    Page 16 of 35 


     


    

 


7.4          
Settlement. The Licensee may not settle or enter into a consent judgment or other voluntary final disposition of
any lawsuit relating to the Licensed Patents, UABRF’s intellectual property rights in the Licensed Patents and/or the Licensee’s
ability to exercise its rights or perform its obligations under this Agreement initiated by it or to which it is a party without
the prior written consent of UABRF, which consent shall not be unreasonably withheld. Neither Party may settle or otherwise dispose
of any lawsuit to which it is a party, which admits liability on the part of the other Party or which requires the other Party
to pay money damages or issue a formal statement without such other Party’s prior written consent.


 


7.5          
Recoveries.


 


		(a)	Lawsuit initiated by the Licensee and in which only the Licensee is a party. With respect
to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which UABRF is not a party, any recovery of damages
shall first be applied in satisfaction of the costs and expenses incurred by the Licensee in bringing such lawsuit, including attorneys’
fees, provided they are reasonably incurred, and any balance shall be treated in accordance with Section 5.5 (Running Royalty Payments).



 


		(b)	Lawsuit initiated by the Licensee and in which UABRF joins.



 


		(i)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which
UABRF is involuntarily joined as a party, any recovery of damages (whether compensatory or punitive in nature) shall first be applied,
pro rata, in satisfaction of the costs and expenses incurred by UABRF arising out of such joinder and participation, including,
but not limited to legal fees and expenses reasonably incurred by legal counsel selected and retained by UABRF to represent it
in such lawsuit, then in satisfaction of the costs and
expenses incurred by the Licensee in bringing such lawsuit, including attorneys’ fees, provided they are reasonably incurred.
Any balance remaining after payment of such costs and expenses, in the case of patent infringement lawsuits, shall be treated in
accordance with Section 5.5 of this Agreement as it pertains to Sales by Licensee.






 






    Page 17 of 35 


     


    

 


		(ii)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which
UABRF voluntarily joins as a party, any recovery of damages (whether compensatory or punitive in nature) shall first be applied
in satisfaction of the costs and expenses incurred by the Parties in bringing such lawsuit, including attorneys’ fees, provided
they are reasonably incurred and shall be applied equally or, in the case of a different agreement between the Parties, in the
same manner as the Parties have agreed to be responsible for the costs and expenses. Any balance remaining after payment of such
expenses shall be treated in accordance with Section 5.5 of this Agreement as it pertains to Sales by Licensee.



 


		(c)	Lawsuit initiated by UABRF. With respect to any lawsuit commenced by UABRF pursuant to Section
7.3(b) above, all recoveries of damages shall belong to UABRF. Furthermore, the Licensee shall pay over to UABRF any payments (whether
or not designated as “royalties”) made by an alleged infringer to the Licensee under any existing or future sublicense
authorizing Licensed Products, up to the amount of UABRF’s unreimbursed litigation expenses (including, but not limited to,
attorneys’ fees reasonably incurred).



 


7.6           Inapplicability
of Licensee’s Rights. Notwithstanding Sections 7.1 – 7.5 above, the rights and obligations of the Licensee under
this article shall not apply to (a) any Licensed Patents in which there are no Valid Patent Claims remaining or (b) any Disclaimed
Licensed Patent.


 


7.7           Patent
Challenges. In the event the Licensee, any of its Affiliates, any Sublicensee or any Third Party at the written urging of any
of these parties intends to challenge the validity or enforceability of any of the Licensed Patents in any manner, including instituting
opposition, declaratory judgment, interference, post-grant review, inter partes review, or re-examination proceeding (a “Patent
Challenge”), the Licensee shall give UABRF at least [*****] prior written notice, which shall include stating the basis for
such Patent Challenge and providing a copy of all relevant prior art or other materials used as the basis for such Patent Challenge.
In the event of a Patent Challenge, Licensee shall: [*****]. In the event of an Unsuccessful Patent Challenge, [*****]. As used
herein, “Unsuccessful” means that, upon the conclusion of the action before the court or other Governmental Authority
in which the Patent Challenge was brought, [*****]. The Licensee represents that it has reviewed the Licensed Patents and as of
the Effective Date is unaware of any reasons why issued patents would not be valid or enforceable or why pending applications would
not be valid or enforceable upon issuance.


 






    Page 18 of 35 


     


    

 


Article
8


Other
Covenants and Agreements


 


8.1           Use
of Names. No Party may, without the prior written consent of the other Party: use (a) the name of the other Party or its Affiliates,
if applicable, (b) the name or image of any Representative of the other Party, or (c) any trade-name, trademark, trade device,
service mark, or symbol owned by the other Party in any publication, marketing or advertising documentation or material; or represent,
either directly or indirectly, that any product or service of the other Party is a product or service of the representing Party
or that it is made in accordance with or utilizes the information or documents of the other Party. Notwithstanding the foregoing,
the Licensee may disclose that it has received a license from UABRF in connection with any Licensed Product, and either Party may
use the name of the other Party to the extent such use is reasonably necessary for complying with Applicable Law.


 


8.2           Publications.
In furtherance of Section 2.3(c) of this Agreement, UABRF or its Affiliates shall submit a copy of any proposed publication or
disclosure containing Proprietary Information to the Licensee at least [*****] prior to submission or disclosure. The Licensee
shall have [*****] days from its receipt to provide written notice to UABRF or its disclosing Affiliate as to (i) specific edits
to remove Licensee’s Proprietary Information prior to publication or disclosure or (ii) the need to delay such publication
or disclosure for a reasonable period of time to undertake Protection Activities. If the Licensee does not provide written notice
of such request to UABRF or its Affiliate within [*****], UABRF or its Affiliate shall be free to publish or disclose to third
parties the proposed publication or disclosure without further obligation to the Licensee.


 


8.3           Insurance
Coverage. Prior to commencing any clinical trial and during the Term, the Licensee shall cause to be in effect through purchase
from a reputable insurance company or, upon the consent of UABRF, through a self-insurance program, at its sole expense, "occurrence
based type" liability insurance coverage or, if the Licensee is unable to obtain “occurrence based type” liability
insurance, a “claims made type” liability insurance coverage (with at least [*****] tail coverage). Such insurance
coverage shall include a contractual endorsement providing coverage for all liability which may be incurred in connection with
this Agreement, including, but not limited to general liability and products liability, and such other type of insurance coverage
required by Applicable Law or which it deems necessary to enable the Licensee to perform its obligations under this Agreement.
All such insurance coverage shall list UABRF and its Affiliates as additional insureds. The Licensee shall provide evidence of
such insurance coverage to UABRF within [*****] of commencing any clinical trial and at least annually thereafter. All such insurance
coverage shall require the insurance provider, or in the case of a self-insurance program, the Licensee, to provide UABRF with
at least [*****] prior written notice of any change in the terms or cancellation of coverage.


 


8.4           Confidentiality.


 


		(a)	Exchange of Proprietary Information. The Parties acknowledge that during the Term
they are likely to share information with each other that they each consider to be confidential and proprietary (“Proprietary
Information”). For the purposes of this Agreement, the Party that discloses Proprietary Information shall be referred to
as the “Disclosing Party”
and the Party receiving the Proprietary Information, the “Receiving Party.”






 






    Page 19 of 35 


     


    

 


		(b)	Nature of Proprietary Information. The Parties agree that information provided to
the other Party shall be deemed to be Proprietary Information if it can reasonably be considered to be proprietary, non-public
information. Any information that is disclosed orally and that could not reasonably be considered to be proprietary and non-public
information will only be deemed to be Proprietary Information if it is , summarized and reduced to writing and identified as “Proprietary”
or “Confidential” in writing to the other Party within [*****] of such disclosure. Notwithstanding the above, the Parties
specifically agree that any reports provided by the Licensee pursuant to this Agreement shall be considered Proprietary Information.



 


		(c)	Restrictions. With respect to all Proprietary Information disclosed to it, the Receiving
Party (i) shall keep it confidential (other than as permitted by this Agreement), (ii) shall store and maintain it with the same
diligence and care as its own proprietary information, but no less than reasonable diligence and care, (iii) may only use it for
the purpose for which it was disclosed by the Disclosing Party, (iv) may not disclose it (other than to Affiliates, Sublicensees
or as permitted by this Agreement), unless such Third Party is contractually bound by confidentiality restrictions at least as
stringent as those contained herein; (v) may not deconstruct, modify or copy it (other than as permitted by this Agreement), and
(vi) may not transfer or assign it to any Third Party (other than as permitted by this Agreement)without the prior written consent
of the Disclosing Party.



 


		(d)	Access to the Proprietary Information. The Proprietary Information may be used by,
and disclosed to, on an “as-needed” basis, the Receiving Party’s Representatives. The Licensee may disclose Proprietary
Information relating to the Licensed Patents to investors, prospective investors, consultants, collaborators and other Third Parties
in the chain of manufacturing and distribution, if and only if, the Licensee obtains from such recipient a written confidentiality
agreement, the provisions of which are at least as protective of UABRF’s Proprietary Information as these set forth in this
section 8.4. Each Party will promptly notify the other Party of any unauthorized use of or access to the Proprietary Information
of which it becomes aware.



 


		(e)	Exceptions to Confidentiality Obligation. The restrictions of confidentiality described
above shall not apply to Proprietary Information (i) which as of the Effective Date or subsequent thereto is or becomes available
to the public without breach of this Agreement, (ii) if it is lawfully obtained from a Third Party not bound by similar confidentiality
and use restrictions and obligations, (iii) if it is known by the Receiving Party prior to disclosure as evidenced by contemporaneous
records, or (iv) if it is at any time developed by the Receiving Party independently of any disclosure made pursuant to this Agreement.
In addition, the confidentiality obligations shall not apply to the Receiving Party if the Receiving Party is legally required
by applicable law, court order or Governmental Authority to disclose the Information, provided the Receiving Party discloses only
the minimum to comply and, if possible and in light of
the circumstances, provides reasonable prior notice to the Disclosing Party to enable it to contest the requirement or to seek
a protective order.






 






    Page 20 of 35 


     


    

 


		(f)	Termination or Expiration of this Agreement. Upon the expiration of the Term, or the earlier
termination of this Agreement, each Receiving Party shall, at the Disclosing Party’s option and upon written notice thereof
to the Receiving Party, return all Proprietary Information, copies and other tangible expressions thereof, to the Disclosing Party
or provide the Disclosing Party with written notice that the Proprietary Information in its possession, or in the possession of
its Representatives, has been destroyed within [*****] after receipt of the Disclosing Party’s written notice to the Receiving
Party requiring the Receiving Party to destroy the Proprietary Information in its possession. The Receiving Party may retain one
archival copy of the Information for purposes of compliance of its obligations under this Agreement.



 


		(g)	Continuing Obligations after Termination/Expiration. The restrictions and obligations
set forth in Section 8.4(c) above shall continue for [*****] from the termination or expiration of this Agreement.



 


Article
9


Term
and Termination


 


9.1           Term.
This Agreement shall commence on the Effective Date and shall continue, unless terminated sooner in accordance with the terms of
this Agreement, until the date of expiration of the last to expire of any Valid Patent Claim (inclusive of any extensions, supplementary
protection certificates or their equivalents) within the Licensed Patents (the “Term”).


 


9.2           Termination
by the Licensee. The Licensee may terminate this Agreement at any time, in its sole discretion, by giving not less than [*****]
prior written notice to UABRF. Upon the reasonable request of UABRF, the Licensee shall provide assistance, at its expense, to
UABRF to enable UABRF to facilitate and effect the transfer of applicable information and documents regarding the Licensed Patents
to a new licensee.


 


9.3           Termination
by UABRF. UABRF shall have the right to immediately terminate this Agreement upon the occurrence of any one or more of the
following events:


 


		(a)	if the Licensee is in material default of any provision of this Agreement or its obligations under
this Agreement and such default has not been remedied within [*****] after receipt of a notice to cure from UABRF;



		(b)	if the Licensee fails to make a payment due under this Agreement and fails to cure such non-payment
within [*****] of receipt of a non-payment notice from UABRF;



		(c)	if the Licensee fails to diligently undertake development and commercialization activities as set
forth in the Development and Commercialization Plan, provided however, Licensee shall be deemed to have demonstrated sufficient
diligence through [*****] or [*****], and [*****] in accordance with [*****];



 






    Page 21 of 35 


     


    

 



 


		(d)	if an examination by UABRF pursuant to Section 6.2 shows an underreporting or underpayment by the
Licensee in excess of [*****] of any amounts due to UABRF under this Agreement in any [*****] period, provided however, any disputed
reporting or payment obligations by Licensee shall not be considered a breach of this provision;



		(e)	if the Licensee, any of its Affiliates, any Sublicensee, or any Third Party at the written urging
of any of these parties brings a Patent Challenge under Section 7.7 of this Agreement;



		(f)	if the Licensee, any of its Affiliates, any Sublicensee, or any Third Party at the written urging
of any of these parties issues a press release, public announcement, or news release alleging invalidity or unenforceability of
any Licensed Patent; or



		(g)	if the Licensee shall become insolvent, shall make an assignment for the benefit of its creditors,
or shall have a petition in bankruptcy filed for or against it.



 


9.4       Effect
of Termination or Expiration. Any termination or expiration of this Agreement will not relieve either Party of any obligation
or liability accrued by Licensee, its Affiliates or Sublicensee prior to such termination or expiration.


 


Article
10


Covenants;
Representations and Warranties; 


Limitations
on UABRF’s Obligations


 


10.1       Both
Parties. Each Party represents and warrants to the other Party that it is duly incorporated, validly existing and in good standing
under the laws of the jurisdiction in which it was formed, it has all necessary corporate power and authority to enter into this
Agreement and to consummate the transactions contemplated hereby, that the execution, delivery and performance of this Agreement
by it will not conflict with or result in a breach of, or entitle any party thereto to terminate, an agreement or instrument to
which it is a party, or by which any of its assets or properties are bound, and that this Agreement has been duly authorized, executed
and delivered by it and constitutes a legal, valid and binding agreement of such Party, enforceable against it in accordance with
its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar
laws affecting creditors’ rights generally.


 


		10.2	The Licensee. The Licensee makes the following representations and warranties to UABRF.



 


		(a)	The Licensee possesses the necessary expertise and skill in the technical areas pertaining to the
Licensed Patents, and to make its own evaluation of the capabilities, safety, utility and commercial application of the Licensed
Patents.



		(b)	Any activity undertaken with the Licensed Patents and the Licensed Products will be conducted in
compliance with all Applicable Laws.



 


		10.3	UABRF. UABRF makes the following representations and warranties to the Licensee.



 


		(a)	UABRF has the right to grant the license under this Agreement and, to the best of its knowledge,
has provided, or will provide, Licensee with all Technical Information and Regulatory Documents
as provided to UABRF by The University of Alabama at Birmingham and/or the Inventors.



 






    Page 22 of 35


     


    

 





		(b)	To UABRF’s best knowledge and based upon information and representations and warranties made
to it by the Inventors, UABRF has no knowledge of any defects to the title and interest in the Licensed Patents and there have
been no claims made against UABRF asserting the invalidity or non-enforceability, and with respect to the Licensed Patents, UABRF
is not aware that any such claims exist.



		(c)	The performance of Management Activities with respect to Disclaimed Licensed Patents will not conflict
with or result in a breach of any of the terms, conditions, or provisions of, or constitute a default under, this Agreement, and
no Third Party shall have any right of claim against the Licensee, with respect to this Agreement or any rights remaining therein.



 


10.3       Limitations
on UABRF’s Representations and Warranties. Except as set forth in this Agreement, UABRF makes no other representations
or warranties of any kind. In particular, UABRF makes no express or implied warranties regarding merchantability, fitness for a
particular purpose, non-infringement of the intellectual property rights of third parties, validity and scope of any Licensed Patents,
the capability, safety, efficacy, utility or commercial application or usefulness for any purpose of any Licensed Patents, or that
UABRF will not grant licenses to one or more Third Parties to make, use or sell products or perform processes that may be similar
to and/or compete with any Licensed Product.


 


10.4       Limitations
on Licensee’s Representations and Warranties. LICENSEE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, REGARDING THE RESULTS OF ITS EFFORTS TO DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY LICENSED PRODUCTS.


 


10.5       No
Obligation of UABRF. Unless otherwise agreed in a writing signed by both Parties, UABRF has no obligation to:


 


		(a)	supervise, monitor, review or otherwise assume responsibility for the production, manufacture,
testing, marketing, sale or disposition of any Licensed Product;



		(b)	furnish any know-how or other information relating to the Licensed Patents, other than as specifically
provided in this Agreement; or



		(c)	bring or prosecute legal action against any Person for infringement of the Licensed Patents or
to defend a Patent Challenge.



 


Article
11


Liability
and Indemnification


 


11.1       No
Indirect, Special or Consequential Liability. None of the Parties shall under any circumstances be liable to any other Party
or any other Party’s Affiliates for indirect, incidental, special or consequential damages (including, but not limited to,
loss of production time, profits, revenue or business) resulting from or in any way related to this Agreement.


 






    Page 23 of 35


     


    

 


11.2       No
Liability of UABRF. Neither UABRF nor any of its Representatives have any liability whatsoever to the Licensee, its
Affiliates or any Sublicensee or any Person for or on account of any injury, loss or damage of any kind or nature, sustained
by, assessed or asserted against, or any other liability incurred by or imposed upon the Licensee, its Affiliates or any
Sublicensee or any Person, arising out of or in connection with or resulting from:


 


		(a)	the use of the Licensed Patents during the Term;



		(b)	the production, use, practice, lease, or sale of any Licensed Product;



		(c)	any advertising or other promotional activities with respect to (a) and/or (b) above;



		(d)	the Licensee’s compliance with, and performance of the Licensee’s representations and
warranties given under, and the Licensee’s obligations pursuant to, this Agreement; or



		(e)	any fraudulent act on the part of one or more of the Inventors that affects the title of the Licensed
Patents.



 


In addition, UABRF’s liability shall
be [*****].


 


Notwithstanding the foregoing, UABRF shall
be responsible and liable for any injury, loss or damage of any kind or nature, sustained by, assessed or asserted against, or
any other liability incurred by or imposed upon the Licensee, any Sublicensee, any of their respective Representatives or any Person,
arising out of or in connection with or resulting from (i) UABRF’s or any of its Representatives’ negligent acts or
omissions, willful malfeasance, or intentional misconduct; (ii) the practice by UABRF of the Licensed Patents prior the Effective
Date; or (iii) any breach of Applicable Law by UABRF or any of its Representatives which is the direct and sole cause of the injury,
loss or damage sustained.


 


11.3       Indemnification
by the Licensee. The Licensee agrees to indemnify and hold UABRF, its Affiliates and their respective Representatives harmless
from and against any and all claims, demands, losses, costs, expenses, deficiencies, liabilities or causes of action of any kind
or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) directly relating
to:


 


		(a)	the use of the Licensed Patents during the Term;



		(b)	the production, use, practice, lease, or sale of any Licensed Product during the Term;



		(c)	any advertising or other promotional activities with respect to (a) and/or (b) above; or



		(d)	the Licensee’s compliance with, and performance of the Licensee’s representations and
warranties given under, and the Licensee’s obligations pursuant to, this Agreement.



 


11.3       Indemnification by
UABRF. UABRF shall indemnify, defend and hold harmless Licensee, its Sublicensees, and each of their Representatives
from and against any and all claims, demands, losses, costs, expenses, deficiencies, liabilities or causes of action of any
kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense)
directly resulting from i) UABRF’s or any of its Representative’s negligence, willful malfeasance, intentional
misconduct, omission or material breach of any term of this Agreement; and ii) UABRF’s practice of the Licensed Patents
prior to the Effective Date;; and iii) UABRF’s compliance with, and performance of UABRF’s representations and
warranties given under, and UABRF’s obligations pursuant to, this Agreement.


 






    Page 24 of 35


     


    

 


Article
12


Miscellaneous


 


12.1       Entire
Agreement. This Agreement is the sole and entire agreement by and between the Parties regarding the subject matter set forth
in this Agreement, and supersedes all prior agreements. All previous negotiations, statements and preliminary instruments by the
Parties with respect to the subject matter hereof are merged in this Agreement.


 


12.2       No
Inducement. No Party has been induced, persuaded or motivated by any promise or representation made by the other Party to enter
into this Agreement.


 


12.3       Independent
Contractors. The Parties are independent contractors. No Party has the authority to bind or act on behalf of the other Party.
The Parties do not intend to create an employer/employee relationship.


 


12.4       No
Third Party Beneficiaries. This Agreement is for the exclusive benefit of the Parties and their successors and permitted assignees.
No other Person shall have any rights under this Agreement, unless and only to the extent permitted by Applicable Law.


 


12.5       Assignment.
The Licensee shall not sell, assign, transfer or otherwise dispose of this Agreement including by operation of law to a Third Party
without the prior written consent of UABRF, which consent shall not be unreasonably withheld, except that Licensee shall be permitted
to assign this Agreement in the case of: (i) an assignment to a wholly owned Affiliate of Licensee, (ii) the sale of substantially
all of the stock or assets of Licensee, or (iii) any merger or acquisition or business combination resulting in a change of control
of Licensee, provided that any assignee (a) shall have the knowledge, expertise and experience to perform this Agreement and (b)
shall ratify this Agreement and abide by all of its terms and conditions provisions. Any attempted assignment of this Agreement
not in compliance with the terms of this subsection will be null and void. No assignment will relieve any Party of the performance
of any accrued obligation that such Party may then have pursuant to this Agreement.


 


12.6       Amendments.
Any and all modifications to this Agreement shall only be effective and binding if in writing and signed by a duly authorized representative
of each Party.


 


12.7       Notices.
Any notice, request, approval or consent required to be given under this Agreement will be sufficiently given if in writing and
delivered to a Party in person, by recognized overnight courier or mailed in such Party’s national postal service, postage
prepaid to the address appearing below such Party’s signature on the last page of this Agreement, or at such other address
as each Party so designates in accordance with these criteria. Notice shall be deemed effective upon receipt if delivered in person
or by overnight courier or five (5) business days after mailing with the Party’s national postal service.


 






    Page 25 of 35


     


    

 


12.8       Disputes.


 


		(a)	Equitable Relief. Either Party may seek temporary equitable and injunctive relief in a court
of competent jurisdiction in the event of a breach or threatened breach by the other Party of its obligations under this Agreement,
without the requirement to post a bond.



 


		(b)	Internal Resolution. In the event of any dispute arising out of or relating to this
Agreement or to a breach thereof, including its interpretation, performance or termination, the Parties shall try to settle such
conflicts amicably between themselves.



 


		(c)	Mediation. In the event the Parties are still unable to resolve the dispute, the dispute
or conflict may then be submitted by a Party to a mediator, mutually agreed to by the Parties, for nonbinding mediation. The Parties
shall cooperate with the mediator in an effort to resolve such dispute.



 


		(d)	Arbitration. If the dispute is not resolved within [*****] days of its submission to the
mediator, either Party may submit the dispute for binding arbitration. The arbitration shall be conducted by one (1) arbitrator,
to be appointed by mutual agreement of the Parties. The arbitration shall be conducted in accordance with the rules and organization
agreed to by the Parties at the time or if no agreement can be reached, by the commercial rules of the American Arbitration Association,
which shall administer the arbitration. The arbitration, including the rendering of the award, shall take place in [*****] and
shall be the exclusive forum for resolving such dispute. The decision of the arbitrator shall be final and binding upon the Parties
and the expense of the arbitration, including, without limitation, the award of attorneys’ fees to the prevailing Party,
shall be paid as the arbitrator determines.



 


12.9       Rights
and Remedies. The rights and remedies provided by this Agreement are cumulative, and the use of any one right or remedy by
any Party shall not preclude or waive the right to use any or all other remedies. Such rights and remedies are given in addition
to any other rights the Parties may have by law, statute, ordinance or otherwise.


 


12.10       Waiver.
No term of this Agreement can be waived except by the written consent of the Party waiving compliance. No waiver of a provision,
breach or default shall apply to any other provision or subsequent breach or default or be deemed continuous, nor will any single
or partial exercise of a right or power preclude any other further exercise of any rights or remedies provided by law or equity.


 


12.11       Severability.
In the event that any provision contained in this Agreement is determined to be invalid, void or illegal, such provision shall
be deemed deleted from the Agreement and shall not affect the validity of the remaining provisions of this Agreement.


 


12.12       Force
Majeure. No Party shall be liable for any failure to perform its obligations under this Agreement to the extent such
failure to perform is due to circumstances reasonably beyond such Party’s control, provided that the affected Party
uses reasonable efforts to overcome or avoid the effects of such cause and continues to perform its obligations to the extent
possible.


 






    Page 26 of 35


     


    

 


12.13       Survivability.
All rights and obligations of the Parties which by intent or meaning have validity beyond or by their nature apply or are to be
performed or exercised after the termination or expiration of this Agreement shall survive the termination or expiration of this
Agreement for the period so specified, if any, or for perpetuity.


 


12.14       Governing
Law. This Agreement, and the application or interpretation hereof, shall be governed exclusively by its terms and by the laws
of the State of Alabama.


 


12.15       Jurisdiction.
The Licensee consents on behalf of itself and its Affiliates to the personal jurisdiction of the federal and state courts located
in the State of Alabama with respect to all claims or other causes of action arising out of this Agreement.


 


12.16       Interpretation.
Whenever used in this Agreement and when required by the context, the singular number shall include the plural and the plural the
singular. Pronouns of one gender shall include all genders, masculine, feminine and neuter.


 


12.17       Captions.
The captions as to contents of particular sections or paragraphs contained in this Agreement are inserted for convenience and are
in no way to be construed as part of this Agreement or as a limitation on the scope of the particular sections or paragraphs to
which they refer.


 


12.18       Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall constitute one
and the same instrument.


 


 


The remainder of this page intentionally
left blank


 






    Page 27 of 35


     


    

 


IN WITNESS WHEREOF, the Licensee
and UABRF have each caused its duly authorized representative to execute this Agreement, effective as of the Effective Date.


 


	UABRF:	 	THE LICENSEE:
	The UAB Research Foundation 	 	Incysus, Ltd.
	 	 	 
	By:	/s/ Authorized Signatory	 	By:	/s/ William Ho
	 	 	Name: 	William Ho
	 	 	Title:	CEO






	 	 
	 	By:	   
	 	Name:	 
	 	Title:	 



 


	Addresses For Notices and Payments:	Address For Notices:
	
        For Delivery by Hand or Courier Service:

         

        The UAB Research Foundation

        Attention: Executive Director

        701 20th Street South

        Administration Building 770

        Birmingham, AL 35233

         

        For Delivery by U.S. Postal Service:

         

        The UAB Research Foundation

        Attention: Executive Director

        1720 2nd Avenue South

        Administration Building 770

        Birmingham, AL 35294-0107
	
        Incysus, Ltd.

        Clarendon House

        2 Church Street

        Hamilton, HM11

        Bermuda

         

         




 






    Page 28 of 35


     


    

 


EXHIBIT A


LICENSED PATENTS 


(dated as of the Effective Date)


 


[*****]


 






    Page 29 of 35


     


    

  


EXHIBIT B


DEVELOPMENT AND COMMERCIALIZATION PLAN


 


[*****]


 






    Page 30 of 35


     


    

 


EXHIBIT C


MILESTONES


 


[*****] 


 






    Page 31 of 35


     


    

 


 


EXHIBIT C 


(Continued)


 


 


[*****]


 






    Page 32 of 35


     


    

 


EXHIBIT D


FORM OF STOCK PURCHASE AGREEMENT


  


 






    Page 33 of 35


     


    

 


EXHIBIT E


FORM OF DEVELOPMENT AND COMMERICIALIZATION
PROGRESS REPORT


 


Licensee Name


Address


City, State,
Zip


 


Progress
Report covering the period January- December, 20__ for the License between Licensee and UABRF dated ________________


 


As required
under Article 3 of the above-referenced license agreement, the following details the progress made during the reporting period
in commercializing the licensed technology.


		§	[*****]



		§	[*****]



 






    Page 34 of 35


     


    

 


EXHIBIT F


RESEARCH PLAN 


 


The following research and development priorities will be addressed.


 


[*****]


 






    Page 35 of 35